Sensus HealthcareSRTS
SRTS
About: Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Employees: 54
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 17
5.51% less ownership
Funds ownership: 29.92% [Q4 2024] → 24.41% (-5.51%) [Q1 2025]
18% less funds holding
Funds holding: 65 [Q4 2024] → 53 (-12) [Q1 2025]
19% less call options, than puts
Call options by funds: $120K | Put options by funds: $148K
44% less capital invested
Capital invested by funds: $33.9M [Q4 2024] → $19M (-$14.9M) [Q1 2025]
50% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 24
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
108%
upside
Avg. target
$11
129%
upside
High target
$12
149%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Anthony Vendetti | 108%upside $10 | Buy Maintained | 19 May 2025 |
HC Wainwright & Co. Yi Chen | 149%upside $12 | Buy Reiterated | 4 Apr 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Is It Worth Investing in Sensus Healthcare (SRTS) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Neutral
Seeking Alpha
1 month ago
Sensus Healthcare, Inc. (SRTS) Q1 2025 Earnings Call Transcript
Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sardano - President & General Counsel Javier Rampolla - Chief Financial Officer Conference Call Participants Yi Chen - H. C. Wainwright Jason Wittis - Roth Capital Jeremy Pearlman - Maxim Group Ben Haynor - Lake Street Capital Markets Operator Good day, and welcome to the Sensus Healthcare First Quarter 2025 Financial Results Conference Call.
Negative
Zacks Investment Research
1 month ago
Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Tops Revenue Estimates
Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.14 per share a year ago.
Neutral
Business Wire
1 month ago
Sensus Healthcare Reports First Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three months ended March 31, 2025. Highlights of the first quarter of 2025 include the following: Revenues were $8.3 million Net loss was $2.6 million, or $(0.16) per share Shipped 21 superficial radiotherapy (SRT.
Negative
Zacks Investment Research
1 month ago
Sensus Healthcare, Inc. (SRTS) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.22, marking a -0.47% move from the previous day.
Neutral
Business Wire
1 month ago
Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments
BOCA RATON, Fla.--(BUSINESS WIRE)--May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout.
Negative
Zacks Investment Research
1 month ago
Earnings Preview: Sensus Healthcare, Inc. (SRTS) Q1 Earnings Expected to Decline
Sensus Healthcare (SRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 month ago
Sensus Healthcare to Report First Quarter 2025 Financial Results and Hold Business Update Conference Call on May 15
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the first quarter of 2025 on Thursday, May 15, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer quest.
Positive
Zacks Investment Research
1 month ago
Is Sensus Healthcare (SRTS) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Negative
Zacks Investment Research
1 month ago
Sensus Healthcare, Inc. (SRTS) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Sensus Healthcare, Inc. (SRTS) closed at $4.69, marking a +1.3% move from the previous day.
Charts implemented using Lightweight Charts™